drugset / Trial / NCT03819218

A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream in Adolescent Subjects

NCT03819218

Phase 2 Terminated 7 enrolled MC2 Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

This is a phase 2, open-label, single-group, multicentre trial in which the investigational product, MC2-01 cream, is investigated in adolescent subjects (age 12 to 16 years, 11 months) with clinically diagnosed extensive psoriasis vulgaris.

Timeline

Start
2018-12-27
Primary completion
2020-12-11
Completion
2020-12-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Calcipotriol Small molecule 0.005 % Topical
Subject betamethasone dipropionate Small molecule 0.064 % Topical

Indications